Trial
NCT05033314
THromboprophylaxis In Sickle Cell Disease With Central Venous Catheters (THIS)
Phase IIITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
University Health Network, Toronto
Collaborators
—
Condition
Sickle Cell Disease
Intervention
Rivaroxaban 10 MG
Why stopped
Study terminated due to slow recruitment.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2025-03-19